Important note

This AI stock analysis for Altimmune is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Altimmune - AI Stock Analysis

Analysis generated December 9, 2024

Company Overview

Altimmune (NASDAQ: ALT) is a clinical-stage biopharmaceutical company focused on developing novel immune-modulating therapies to treat liver disease and immune-mediated diseases. The company's pipeline includes a mix of therapeutic candidates targeting hepatitis B, non-alcoholic steatohepatitis (NASH), and other chronic diseases. Its strategic focus on innovative therapies places it at the cutting edge of treatment for serious health conditions, with notable potential for long-term growth.

Fundamental Analysis

Altimmune's financial health reveals both strengths and areas for caution. The revenue for the last quarter was $5,000, mirroring the previous quarter’s revenue, thus exhibiting stability; however, it marks a staggering decrease of 98.62% compared to the same quarter last year. This significant drop can be a critical area of concern as it may indicate underlying challenges in maintaining sales momentum or attracting new business. Net income for the last quarter stood at $23M, reflecting a 7.28% increase from the previous quarter, suggesting a positive trend in profitability. However, a broader look shows a 10.52% decline when compared to the same quarter last year, indicating that while recent growth is promising, there are year-over-year profitability challenges. EBITDA for the last quarter was at $0, demonstrating a 100% increase compared to the quarter before, and the same period last year. This is an essential positive factor pointing towards enhanced operational efficiency and reduced adjusted losses, suggesting potential recovery and improved business operations.

Technical Analysis

Currently, Altimmune's stock is priced at $9.64, showing a robust short-term increase of 25.52% compared to a month ago. The stock price also witnessed a 48.77% rise when compared to a year ago, indicating a positive long-term sentiment and trend. The bullish trend is further confirmed by the 10-day simple moving average (SMA10) at $9.07, higher than the previous SMA10 of $8.97, suggesting that the stock price is on an upward trajectory. However, the relative strength index (RSI) currently stands at 72.6, signifying a potentially overbought and bearish condition. Investors might want to be cautious about a possible short-term correction.

Alternative Data Analysis

Reviewing the alternative data gives additional insights into Altimmune's current and future performance. The company has maintained a constant number of open job positions at 1, which signifies stability and possible future growth. The visitor trend on Altimmune’s website has reported a 47% decrease in the last couple of months, suggesting declining customer interest or engagement. Conversely, the company's Twitter page saw a 4% increase in followers reaching 1,500, indicating a growing social media presence and public interest. Lastly, based on AltIndex’s AI score, Altimmune receives a score of 58, signifying a 'hold' recommendation. The AI score amalgamates fundamental, technical, and alternative data to predict stock performance.

Conclusion and Recommendation

Altimmune exhibits mixed signals across different analyses. The financial performance displays both encouraging signs of growth and worrisome areas requiring attention, particularly the significant decrease in revenue year-over-year. Technical indicators reveal a bullish trend, yet caution is warranted due to an overbought RSI. Alternative data presents a balanced picture, with positive activity on social media and concerning drops in website traffic. Investors should consider a 'hold' position on Altimmune's stock, reflecting the current complexities and mixed performance indicators. Monitoring the company's future quarterly results, alongside social media and job posting trends, can provide further clarity on long-term investment potential.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.